Perfluorohexyloctane

(Miebo®)

Perfluorohexyloctane

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormOphthalmic solution (topical; 100% perfluorohexyloctane)
Drug ClassSemifluorinated alkanes
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of the signs and symptoms of dry eye disease (DED).

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Perfluorohexyloctane (Miebo) is indicated for the treatment of signs and symptoms associated with Dry Eye Disease (DED), demonstrating effectiveness in improving key indicators such as eye dryness score, ocular surface disease index, lipid layer thickness, and total corneal fluorescein staining.
  • The information was derived from a single study categorized under Systematic Reviews / Meta-Analyses.
  • Compared to control groups or other treatments for DED, Miebo showed superior performance in almost all studied variables except tear film break-up time where controls had a slight advantage. This suggests potential benefits from combination therapy or additional interventions targeting this specific aspect.
  • In terms of safety profile, perfluorohexyloctane has been associated with a low incidence of treatment-emergent adverse events, indicating it as potentially safer than traditional substitutes or anti-inflammatory medications used for DED, which may have more significant side effects.
  • High patient satisfaction was noted during the use of Miebo, suggesting its suitability for long-term management strategies required by chronic conditions like DED.
  • While no specific subgroup analyses were detailed, findings suggest broad applicability across different patient subsets; however, future research could help clarify its benefits specifically tailored towards certain demographics.

Product Monograph / Prescribing Information

Document TitleYearSource
Miebo (perfluorohexyloctane) Prescribing Information. 2023Bausch & Lomb Americas Inc., Bridgewater, NJ

Systematic Reviews / Meta-Analyses